SFE Investment Counsel Has $3.46 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

SFE Investment Counsel grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.1% during the 4th quarter, HoldingsChannel reports. The firm owned 17,629 shares of the medical research company’s stock after purchasing an additional 690 shares during the quarter. SFE Investment Counsel’s holdings in IQVIA were worth $3,464,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Performance Advisors LLP acquired a new stake in IQVIA during the 3rd quarter worth $27,000. Synergy Asset Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth about $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Assetmark Inc. grew its position in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the period. Finally, Concord Wealth Partners bought a new stake in IQVIA during the 3rd quarter worth approximately $57,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IQV shares. TD Cowen reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. The Goldman Sachs Group cut their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Bank of America decreased their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $251.67.

IQVIA Stock Down 1.6 %

Shares of IQV opened at $197.64 on Thursday. The stock’s 50-day moving average price is $200.66 and its two-hundred day moving average price is $218.67. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a market capitalization of $35.87 billion, a PE ratio of 26.35, a PEG ratio of 2.25 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.